📰 Affimed News
Affimed News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Affimed. Real-time updates on events, politics, business and more.
May 18, 2024
Affimed (NASDAQ:AFMD – Get Free Report) was the target of a significant drop in short interest during the month of April. As of April 30th, there was short interest totalling 204,100 shares, a drop of 7.0% from the April 15th total of 219,400 shares. Based on an average daily volume of 94,600 shares, the short-interest […]
April 4, 2024
Cantor Fitzgerald reissued their overweight rating on shares of Affimed (NASDAQ:AFMD – Free Report) in a report published on Monday morning, Benzinga reports. Several other analysts also recently weighed in on the stock. StockNews.com started coverage on shares of Affimed in a research report on Tuesday, January 2nd. They issued a sell rating on the […]
April 1, 2024
Research Analysts’ price target changes for Monday, April 1st: Apple (NASDAQ:AAPL) had its target price lowered by Loop Capital from $185.00 to $170.00. Loop Capital currently has a hold rating on the stock. Ameris Bancorp (NASDAQ:ABCB) had its target price lowered by Truist Financial Co. from $60.00 to $54.00. The firm currently has a buy […]
February 16, 2024
Affimed (NASDAQ:AFMD – Get Free Report) passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $0.53 and traded as high as $0.60. Affimed shares last traded at $0.58, with a volume of 740,235 shares changing hands. Analysts Set New Price Targets AFMD has […]
January 6, 2024
StockNews.com initiated coverage on shares of Affimed (NASDAQ:AFMD – Free Report) in a research note issued to investors on Tuesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Other analysts also recently issued reports about the company. HC Wainwright restated a buy rating and issued a $5.00 price objective on shares […]
January 5, 2024
StockNews.com assumed coverage on shares of Affimed (NASDAQ:AFMD – Free Report) in a research note released on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock. AFMD has been the subject of a number of other reports. Cantor Fitzgerald restated an overweight rating and set a $7.00 price objective on shares of […]
December 28, 2023
StockNews.com assumed coverage on shares of Affimed (NASDAQ:AFMD – Free Report) in a report released on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. A number of other brokerages have also recently issued reports on AFMD. HC Wainwright restated a buy rating and set a $5.00 price objective on shares of […]
December 21, 2023
StockNews.com assumed coverage on shares of Affimed (NASDAQ:AFMD – Free Report) in a research note released on Sunday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Several other equities analysts also recently weighed in on AFMD. Cantor Fitzgerald reaffirmed an overweight rating and issued a $7.00 target price on shares of […]
December 17, 2023
Research analysts at StockNews.com assumed coverage on shares of Affimed (NASDAQ:AFMD – Get Free Report) in a note issued to investors on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock. A number of other research firms also recently weighed in on AFMD. HC Wainwright restated a “buy” rating and issued a […]
December 15, 2023
Shares of Affimed (NASDAQ:AFMD – Get Free Report) have earned a consensus rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target […]